Ocular Surgery News U.S. Edition Current Issue
The following articles appeared in the print edition of Ocular Surgery News U.S. Edition.
Table of Contents
- Treatment for thyroid eye disease enters new era, shows potential for brighter future Michela Cimberle
-
- Be mindful of anti-VEGF injection speed, volume in patients with severe glaucoma Eamon N. Dreisbach
- Comprehensive tests needed to determine driving safety in patients with glaucoma Anthony DeFino
- DSEK still useful in challenging corneal transplant cases Alex Young
- Eye drop could provide noninvasive approach to DME treatment Alex Young
- EyeBio closes Series A financing extension with $130 million
- Gene therapy improves diabetic retinopathy severity at 1 year in phase 2 trial Alex Young
- Oculoplastic surgeons should switch to frontalis flap surgery in pediatric patients Anthony DeFino
- Slit lamp cross-linking improves access to care, reduces costs Alex Young
-
- VIDEO: Analysis finds similar BCVA, superior CST for faricimab vs. aflibercept in DME Marco A. Zarbin, MD, PhD; David W. Mullin
- VIDEO: Avacincaptad pegol shows positive GA reduction, safety profile at 2 years Arshad Khanani, MD, MA, FASRS; Anthony DeFino
- VIDEO: IOL with bimatoprost-delivery platform shows promise for long-term IOP lowering Preeya K. Gupta, MD; David W. Mullin
- VIDEO: OmniVu IOL system shows stability, good refractive predictability Daniel H. Chang, MD; Anthony DeFino
- VIDEO: Virtual headset offers alternative to eye patching for amblyopia treatment Rupa Wong, MD; Anthony DeFino
- Xipere receives Category 1 CPT code
- Mastering your fears John B. Pinto
- Spectral domain OCT used for assessment of corneal allogenic intrastromal ring segments Dhivya Ashok Kumar, MD, FRCS, FICO, FAICO; Ashvin Agarwal, MD; Soosan Jacob, MS, FRCS, DNB
-
- Older man experiences trauma after IOL implantation William Warr Binotti, MD; Amal Alwreikat, MD
- Ophthalmologists need to play early role in diagnosing thyroid eye disease Richard L. Lindstrom, MD
- Will teprotumumab supplant traditional options in the treatment of thyroid eye disease?
- Do not let a patient’s proxy sway the premium surgery process Mitchell A. Jackson, MD